Skip to main content

Table 1 Characteristics of Cases and Controls

From: Relation of therapies for ankylosing spondylitis and psoriatic arthritis to risk of myocardial infarction: a nested case control study

  AS P-value PsA P-value
MI Cases Controls MI Cases Controls
Subjects, n 237 894   404 1596  
Female, n (%) 110 (46.4%) 406 (45.4%) 0.7836 167 (41.3%) 660 (41.4%) 0.9951
Age, mean +/− SD 63.0 +/−  11.3 62.8 +/− 11.0 0.7100 61.5 + −  11.2 61.4 + −  11.2 0.8300
Chronic kidney disease, n (%) 13 (5.5%) 36 (4.0%) 0.3269 22 (5.4%) 45 (2.8%) 0.0088
Diabetes, n (%) 62 (26.2%) 191 (21.4%) 0.1152 138 (34.2%) 329 (20.6%) < 0.0001
Ischemic heart disease, n (%) 66 (27.8%) 131 (14.7%) < 0.0001 100 (24.8%) 209 (13.1%) < 0.0001
Liver disease, n (%) < 11a (< 5.0%) 22 (2.5%) NSa 20 (5.0%) 58 (3.6%) 0.2221
Peptic ulcer disease, n (%) 58 (24.5%) 233 (26.1%) 0.6186 71 (17.6%) 297 (18.6%) 0.6316
Psoriasis, n (%) 42 (17.7%) 173 (19.4%) 0.5697 259 (64.1%) 1073 (67.2%) 0.2347
Rheumatoid arthritis, n (%) 76 (32.1%) 237 (26.5%) 0.0891 99 (24.5%) 340 (21.3%) 0.1649
Body mass index > 30 kg/m2), n (%) 33 (13.9%) 104 (11.6%) 0.3365 75 (18.6%) 201 (12.6%) 0.0019
Statin use, n (%) 95 (40.1%) 308 (34.5%) 0.1075 147 (36.4%) 565 (35.4%) 0.7118
Smoking status, n (%) 28 (11.8%) 54 (6.0%) 0.0023 41 (10.1%) 76 (4.8%) < 0.0001
Rheumatology visit in year prior to diagnosis, n (%) 103 (43.5%) 406 (45.4%) 0.8200 214 (53.0%) 911 (57.1%) 0.0200
ESR/CRP ordered in year prior to diagnosis, n (%) 95 (40.1%) 349 (39.0%) 0.7693 175 (43.3%) 651 (40.8%) 0.3567
  1. P values were labeled as non-significant, or NS, when p was > 0.05 and was unable to be reported due to the risk of calculating small numbers of subjects (< 11)
  2. SD Standard deviation, ESR Erythrocyte sedimentation rate, CRP c-reactive protein, NS Non-significant
  3. aCounts under 11 subjects were not reported to prevent inadvertent subject identification